FDA issues final guidance on BCS-based biowaivers

Guidelines/ | Posted 11/06/2021 comments 0
Guidance V13F21

The US Food and Drug Administration (FDA) has published final guidance on ‘M9 Biopharmaceutics Classification System (BCS)-Based Biowaivers’. The guidance was prepared under the auspices of the...

More >
Top 3 Most Read
Interchangeability V18K30
Different approaches to the interchangeability of biosimilars
Posted 05/03/2021

The interchangeability of biosimilars can sometimes be an emotive subject. Despite rese...

Regulation-V13H16
Regulatory challenges with biosimilars
Posted 08/01/2021

The World Health Organization (WHO) Expert Committee on Biological Standardization adop...

EU-US V19C08
How do the biosimilar markets in the US and Europe compare?
Posted 19/02/2021

Authors discuss how the biosimilar markets in the US and Europe compare in a report pro...

Home/Non‐Biological Complex Drugs
Liposome V15L11

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft guidan...

More >